Article Sidebar
Published:
Sep 25, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Comparison of gemcitabine/carboplat in versus paclitaxel/cisplatin for the management of non small cell lung cancer
Abstract
Purpose: To determine the comparative efficacy and toxicity of gemcitabine/carboplatin and paclitaxel/cisplatin in patients with completely resected stage IIa - IIIa non-small cell lung cancer (NSCLC).
Methods: Sixty eligible NSCLC patients treated in Funan County People's Hospital were enrolled and assigned to two groups by randomization (n = 30 each). One group (CG group) received the combination of gemcitabine and carboplatin, while the second group (CP group) received a combination of cisplatin and paclitaxel. Efficacy was assessed based on 2-year progression-free survival, while adverse reactions were recorded to assess the toxicity of the chemotherapy treatments.
Results: No marked difference was found in the 2-year relapse-free survival in the two groups with similar clinical baseline characteristics after follow-up (60 % in CG group vs. 56.67 % in CP group, p = 0.826). Specifically, no significant difference was found between the two groups with regard to incidence of local metastases, distant metastases, or brain tissue metastases within 2 years, and there were no treatment-related deaths. CG group was more likely to develop leukopenia (93.33 % vs. 63.33 % for CP group, p = 0.04), but no significant difference was observed for other adverse effects such as anemia, vomiting, and nausea.
Conclusion: This study shows that adjuvant treatment using carboplatin and gemcitabine produces the same therapeutic efficacy as cisplatin and paclitaxel, but exhibits higher toxicity levels than the latter.
